Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.79 |
| ▸ | BRAF | P15056 | 11/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.78 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.78 |
| ▸ | PLK4 | O00444 | 1/20 | 0.78 |
| ▸ | ACOX3 | O15254 | 1/20 | 0.78 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.78 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.78 |
| ▸ | JAK2 | O60674 | 1/20 | 0.78 |
| ▸ | ERN1 | O75460 | 1/20 | 0.78 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.78 |
| ▸ | STK10 | O94804 | 1/20 | 0.78 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.78 |
| ▸ | RAF1 | P04049 | 1/20 | 0.78 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.78 |
| ▸ | LCK | P06239 | 1/20 | 0.78 |
| ▸ | FYN | P06241 | 1/20 | 0.78 |
| ▸ | CDK1 | P06493 | 1/20 | 0.78 |
| ▸ | FES | P07332 | 1/20 | 0.78 |
| ▸ | CSF1R | P07333 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241121 | 0.95 | BRAF (0.79) | ABL1BRAFMAPK14RIPK1PLK4 | |
| SCHEMBL2243259 | 0.94 | ABL1 (0.78) | ABL1BRAFMAPK14RIPK1PLK4 | |
| SCHEMBL2246323 | 0.94 | ABL1 (0.77) | ABL1BRAFMAPK14RIPK1PLK4 | |
| SCHEMBL2242801 | 0.94 | ABL1 (0.79) | ABL1BRAFMAPK14RIPK1PLK4 | |
| SCHEMBL2242285 | 0.94 | ABL1 (0.79) | ABL1BRAFMAPK14RIPK1PLK4 | |
| SCHEMBL2241374 | 0.94 | BRAF (0.69) | ABL1BRAFMAPK14RIPK1PLK4 | |
| SCHEMBL31265677 | 0.94 | ABL1 (0.79) | ABL1BRAFMAPK14RIPK1PLK4 | |
| SCHEMBL2241243 | 0.93 | ABL1 (0.75) | ABL1BRAFMAPK14RIPK1PLK4 | |
| SCHEMBL2243266 | 0.93 | BRAF (0.80) | ABL1BRAFMAPK14RIPK1PLK4 | |
| SCHEMBL2243163 | 0.93 | BRAF (0.73) | ABL1BRAFMAPK14RIPK1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | claimed |
| EP-2044053-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | claimed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2044053-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | UMPS, SLC14A1, CPS1 | ABL1 3359/4885BRAF 338/4885MAPK14 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.